Literature DB >> 8667612

Effect of poly(vinylsulfonate) on murine AA amyloid: a high-resolution ultrastructural study.

S Inoue1, P G Hultin, W A Szarek, R Kisilevsky.   

Abstract

In experimental murine inflammation-associated amyloidosis (AA amyloidosis), an interaction between heparan sulfate and serum amyloid A (SAA), the AA precursor, has been demonstrated and is believed to play an important role in AA amyloidogenesis. Poly(vinylsulfonate) sodium salt (PVS) can arrest AA amyloid induction and cause established amyloid deposits to regress. PVS is thought to have this property by virtue of limited anionic structural similarities it has to heparan sulfate. In the present study, a comparison has been made of the in situ light microscopic and high-resolution ultrastructure of amyloid deposits before and after PVS treatment. As shown recently in situ, AA fibrils from untreated mice are composed of an outer layer of heparan sulfate proteoglycan and a 1- to 2-nm filament network of AA protein. This layer encloses a microfibril-like structure composed of chondroitin sulfate proteoglycan wound around a core of amyloid P component. After treatment with PVS, both the heparan sulfate proteoglycan and the AA filament network are lost from the fibrils, and the more central portion disintegrates into the chondroitin sulfate proteoglycan with associated amyloid P subunits. These findings add further support to the concept that heparan sulfate proteoglycan is important in amyloid fibril structure, and interference with its binding interactions with the amyloid filament protein provides a point of therapeutic attack.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8667612

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  9 in total

Review 1.  Amyloidosis and the respiratory tract.

Authors:  J D Gillmore; P N Hawkins
Journal:  Thorax       Date:  1999-05       Impact factor: 9.139

2.  Antibody-mediated resolution of light chain-associated amyloid deposits.

Authors:  R Hrncic; J Wall; D A Wolfenbarger; C L Murphy; M Schell; D T Weiss; A Solomon
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 3.  Amyloid accomplices and enforcers.

Authors:  Andrei T Alexandrescu
Journal:  Protein Sci       Date:  2004-12-02       Impact factor: 6.725

4.  Development and evaluation of agents for targeting visceral amyloid.

Authors:  Jonathan S Wall; Alan Solomon; Stephen J Kennel
Journal:  Tijdschr Nucl Geneeskd       Date:  2011-12

5.  Amyloid and inflammation.

Authors:  Peter D Gorevic
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-25       Impact factor: 11.205

6.  In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides.

Authors:  Jonathan S Wall; Tina Richey; Alan Stuckey; Robert Donnell; Sallie Macy; Emily B Martin; Angela Williams; Keiichi Higuchi; Stephen J Kennel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-01       Impact factor: 11.205

7.  Quantitative tomography of early-onset spontaneous AA amyloidosis in interleukin 6 transgenic mice.

Authors:  Jonathan S Wall; Tina Richey; Amy Allen; Robert Donnell; Steve J Kennel; Alan Solomon
Journal:  Comp Med       Date:  2008-12       Impact factor: 0.982

8.  Inhibition of amyloid A amyloidogenesis in vivo and in tissue culture by 4-deoxy analogues of peracetylated 2-acetamido-2-deoxy-alpha- and beta-d-glucose: implications for the treatment of various amyloidoses.

Authors:  Robert Kisilevsky; Walter A Szarek; John B Ancsin; Elena Elimova; Sandra Marone; Shridhar Bhat; Ali Berkin
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

9.  Cellular response of cardiac fibroblasts to amyloidogenic light chains.

Authors:  Vickery Trinkaus-Randall; Mary T Walsh; Shawn Steeves; Grace Monis; Lawreen H Connors; Martha Skinner
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.